Healthcare

• International store sales grew 30.2% with like-for-like growth of 15.8% for the quarter ended 30 September 2026 on a constant currency basis

• Resales rose 36% year-on-year in Q3, driven byDemandacross established villages, with Canterbury a standout at 63 sales versus 37 in Q2.

• Telix has completed enrollment in its Phase 3 BiPASS study and is planning an NDA submission to the FDA.

• The U.S. FDA approved Pixclara for glioma imaging, marking the first approved imaging agent for this indication in the United States

Medibank Private Limited (ASX:MPL) reported FY26 revenue from external customers of AUD 9,115.2 million, an increase of 5.9%. Group operating profit rose 6.7% to AUD 813.5 million. Underlying net profit after tax increased 2.9% to AUD 636.8 million, while statutory profit attributable to shareholders …

The agreement provides Anagenics with an upfront cash amount on completion, alongside an additional sum representing outstanding royalties accumulated under the prior licence arrangement for the current quarter. The forward-looking element of the deal consists of quarterly earn-out payments calculated as a percentage of …

HighlightsNeurizon Therapeutics has completed aPlacementand launched a Share Purchase Plan to eligible shareholders, with the proceeds supporting the company's funding position through to the anticipated topline results from the HEALEY ALS Platform Trial in late Q2 2027.The company has redeemed all remaining convertible notes …